Literature DB >> 3692614

Antimicrobial chemotherapy in patients with cystic fibrosis.

J P Guggenbichler1, J Schneeberger.   

Abstract

The treatment of exacerbations of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis is unsatisfactory. Serum concentrations and urinary excretion of cephalexin, epicillin, azlocillin, ticarcillin, trimethoprim-sulfa and gentamicin useful in the treatment of these infections were investigated in cystic fibrosis patients suffering from pulmonary infections. The data were compared to those found in non-cystic fibrosis children treated with antibiotics for other reasons. Cephalexin and trimethoprim are absorbed at a slower rate; epicillin, azlocillin, ticarcillin sulfonamides were eliminated at a faster rate by the kidneys which was unique to patients with cystic fibrosis. Gentamicin is also eliminated faster. Further investigations disclosed that a considerable amount of drug is eliminated by tubular secretion in addition to the regular glomerular filtration in patients with cystic fibrosis. Creatinine clearance values were determined in these patients and found to be normal. By doubling the dose of gentamicin and administration as infusion over 90 min, higher serum and tissue concentrations were achieved without being in the toxic range. The clinical relevance of these investigations was determined in 36 patients and 48 episodes of infection with P. aeruginosa. Patients received gentamicin 4 mg/kg BW as i.v. infusion over 90 min q. 8 h and azlocillin or ticarcillin 120-160 mg/kg BW q. 8 h, applied 4 h later. In 14 patients respectively 27 episodes, pseudomonas was eradicated from the sputum for a minimum of three weeks, and in most of them for 12-24 weeks. No side effects were observed from the higher doses of aminoglycosides.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3692614     DOI: 10.1007/bf01647752

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Antibiotic therapy in cystic fibrosis: evaluation of clinical trials.

Authors:  A L Smith
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

2.  Kill kinetics of bacteria under fluctuating concentrations of various antibiotics. II. Description of experiments.

Authors:  P König; J P Guggenbichler; E Semenitz; W Foisner
Journal:  Chemotherapy       Date:  1986       Impact factor: 2.544

3.  Bioavailability of oral antibiotics in cystic fibrosis.

Authors:  J P Guggenbichler; G Kienel
Journal:  Monogr Paediatr       Date:  1979

4.  Aminoglycoside clearance in patients with cystic fibrosis.

Authors:  E Finkelstein; K Hall
Journal:  J Pediatr       Date:  1979-01       Impact factor: 4.406

Review 5.  Cystic fibrosis--a challenging long-term chronic disease.

Authors:  L W Matthews; D Drotar
Journal:  Pediatr Clin North Am       Date:  1984-02       Impact factor: 3.278

6.  An enzymatic radioassay for gentamicin.

Authors:  R V Case; L M Mezei
Journal:  Clin Chem       Date:  1978-12       Impact factor: 8.327

7.  Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis.

Authors:  W J Jusko; L L Mosovich; L M Gerbracht; M E Mattar; S J Yaffe
Journal:  Pediatrics       Date:  1975-12       Impact factor: 7.124

8.  Pharmacokinetics of azlocillin in children with cystic fibrosis.

Authors:  T Bergan; H Michalsen
Journal:  Arzneimittelforschung       Date:  1979

9.  [Pharmacokinetic of antibiotics in patients with mucoviscidosis (author's transl)].

Authors:  J P Guggenbichler; K Pillwein; F Schabel; R Rohrer
Journal:  Padiatr Padol       Date:  1981

10.  Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology.

Authors:  M L Vasil
Journal:  J Pediatr       Date:  1986-05       Impact factor: 6.314

  10 in total
  4 in total

Review 1.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

2.  Selection of antibiotics for treatment and prophylaxis of staphylococcal infections in cystic fibrosis patients.

Authors:  A Bauernfeind; B Przyklenk; C Matthias; R Jungwirth; R M Bertele; K Harms
Journal:  Infection       Date:  1990 Mar-Apr       Impact factor: 3.553

Review 3.  Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.

Authors:  M LeBel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

4.  Epidemiology of Staphylococcus aureus in patients with cystic fibrosis.

Authors:  C Branger; J M Fournier; J Loulergue; A Bouvet; P Goullet; A Boutonnier; C de Gialluly; G Couetdic; M Chomarat; M C Jaffar-Banjee
Journal:  Epidemiol Infect       Date:  1994-06       Impact factor: 2.451

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.